Search | Clinical Trials Finder

Conditions: Hemophilia B
Interventions: IB1001; Biological
Lead sponsor: Medexus Pharma, Inc.; Industry
Eligibility: Up to 12 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Indianapolis, Indiana • Houston, Texas

Conditions: Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions: Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP); Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anticoagulant-related Major Bleed
Interventions: Andexanet alfa, 4F-PCC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 5,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Agoura Hills, California

Conditions: Hemophilia B
Interventions: CSL222 (AAV5-hFIXco-Padua); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more

Conditions: Hemophilia A and B, Liver Transplantation
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Peoria, Illinois + 12 more

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Conditions: Hemophilia B
Interventions: Gene Transfer, scAAV2/8-LP1-hFIXco; Genetic · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 3
States / cities: Stanford, California • Memphis, Tennessee • Temple, Texas

Conditions: Hemophilia A
Interventions: Emicizumab, FEIBA, rFVIIa; Drug
Lead sponsor: Emory University; Other
Eligibility: 6 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua (AMT-061); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more

Conditions: Hemophilia B
Interventions: IB1001, nonacog alfa; Biological
Lead sponsor: Medexus Pharma, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Hemophilia A
Interventions: Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC); Biological
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemophilia
Interventions: Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bleeding
Interventions: 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hemophilia B, Hemophilia B, Moderately Severe or Severe
Interventions: BE-101; Drug
Lead sponsor: Be Biopharma; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Davis, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 2 more

Conditions: Acute Major Bleeding
Interventions: Octaplex; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Torrance, California • Gainesville, Florida • West Palm Beach, Florida + 6 more

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: N9-GP, ALPROLIX®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Chicago, Illinois • Peoria, Illinois + 4 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Recombinant Factor VIIa BI (rFVIIa BI); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hemophilia A
Interventions: Factor IX; Drug
Lead sponsor: Tulane University; Other
Eligibility: 12 Years to 120 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Hemophilia, Menstrual Flow Excessive
Interventions: Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coagulation Disorder
Interventions: TAK-330, SOC 4F-PCC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more

Conditions: Hemophilia B
Interventions: CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 138 Months to 206 Months · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 5
States / cities: Orange, California • Gainesville, Florida • Atlanta, Georgia + 2 more

Conditions: Haemophilic Pseudotumour
Interventions: Emicizumab; Drug
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions: BE1116, FFP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more

Search by objective public record fields.

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

ATHN 11: Liver Transplantation Outcomes Study

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Dose Confirmation Trial of AAV5-hFIXco-Padua

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Treatment of Hemophilia A Patients With FVIII Inhibitors

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)